WeVote

Bill

Bill

SB 65

Substance abuse services; authorizing the possession, acquisition, distribution and administration of emergency opioid antagonists and adulterant test strips by any person. Effective date. Emergency.

2026 Regular Session Introduced by Tim Turner and 1 co-sponsor

Oklahoma law now permits any person to carry, obtain, distribute, and administer opioid overdose reversal drugs without medical licensure, enabling rapid emergency response to overdoses.

Approved by Governor 05/12/2026
0
WeVote Research Nonpartisan
Bill Summary · SB 65

Legislative bill overview

SB 65 expands access to emergency opioid antagonists (primarily naloxone/Narcan) by removing legal barriers that currently restrict administration to licensed medical professionals. The bill authorizes any person to possess, acquire, distribute, and administer these life-saving medications, treating them similarly to other states' "Good Samaritan" opioid access laws.

Why is this important

Opioid overdose deaths remain a significant public health crisis. Naloxone administered quickly can reverse overdose and save lives, but delays in obtaining or administering it from licensed professionals can be fatal. Removing legal restrictions enables bystanders, family members, and community responders to act immediately in emergency situations, potentially reducing preventable deaths.

Potential points of contention

  • Liability concerns: Whether businesses, organizations, or individuals distributing naloxone face liability if administration causes harm or proves ineffective
  • Regulation and training: Whether the bill should require basic training/certification for administration or if completely unrestricted access creates safety risks
  • Cost and access equity: Who funds naloxone distribution and whether this adequately reaches underserved communities where overdose rates are highest, or if it primarily benefits those who can afford it

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.